Navigation Links
Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant
Date:7/30/2014

SAN FRANCISCO, July 30, 2014 /PRNewswire/ -- A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH is a human protein and an important inhibitor of the complement system.

The study shows that post-transplant treatment with C1-INH results in significant increases in the levels of complement components 3 and 4, suggesting that C1-INH inhibits activation of the complement system following transplantation. Antibody-mediated rejection is a major cause of kidney transplant failure and is often associated with activation of complement, a set of proteins that work with antibodies and play a role in the development of inflammation and tissue damage.

"Antibody-mediated rejection is a severe form of rejection that can occur in patients who have undergone a kidney transplant," said Stanley C. Jordan, M.D., Kidney Transplant, Cedars-Sinai Medical Center in Los Angeles, and one of the study's investigators. "Our findings provide additional insight into how C1-INH affects complement activation and represent an important advance in the study of complement-targeting therapeutics."

The placebo-controlled, single-center study evaluated 20 highly sensitized patients, meaning they already had antibodies against donor organs. Subjects were randomized to receive either placebo or 20 IU/kg of C1-INH, administered intra-operatively, then twice a week for seven additional doses. Patients were desensitized with immunoglobulin and rituximab, decreasing the patient's antibody levels prior to transplant.

According to study findings, fewer patients who were administered C1-INH developed serious adverse events compared to those administered placebo (20 percent versus 30 percent). C1-INH functi
'/>"/>

SOURCE CSL Behring
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... May 30, 2015 CTI BioPharma Corp. (CTI ... business (NYSE: BAX ) today announced data from ... pacritinib for the treatment of myelofibrosis – in a ... of the American Society of Clinical Oncology (ASCO), May ... Pacritinib is an investigational oral multikinase inhibitor with ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... CHAPEL HILL, N.C. , May 29, 2015 ... the medical affairs function into roles involving clinical ... As its responsibilities have grown, Medical Affairs ... the function as a global group. And while ... sometimes find it challenging to identify strong performance ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2
... CHICAGO, Oct. 9 Chicago-based Celsis International, a leading ... completed its public-to-private transaction process and will de-list from ... privately held company. , "Celsis has a very strong ... yet our strong financial results were not being reflected ...
... , BUDAPEST, Hungary, October 9 ... General of the Commission of,the European Communities approved the ... Consortium (CancerGrid) to,TargetEx. , "This ... in,Hungary - "and an appreciation of our scientific potential ...
... ... the Development and Optimization of Crystallization Processes, a method will be presented which facilitates ... of qualitative supersaturation trajectories. , ... (PRWEB) October 9, 2009 -- The quantitative use of in situ ATR-FTIR ...
Cached Biology Technology:Chicago-Based Celsis International Goes Private 2TargetEx Leads the European Cancer Research Consortium 2Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes 2
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Conservation Society and other organizations released a new study ... ranching facilities in Argentina to ensure the safety of ... focus on two crocodilian species, the yacare caiman and ... ranches for sustainable harvest. The research team sought to ...
... May 13, 2010 (Toronto) A new study involving ... a gene connected with a type of intellectual disability called ... has identified this gene that, when defective, leads to Joubert ... issue of Cell . This international study combined ...
... CAMBRIDGE, Mass. -- At first glance, a diagram of the ... hopelessly complex, and efforts to control such a system futile. ... new computational model that can analyze any type of complex ... critical points that can be used to control the entire ...
Cached Biology News:Wildlife Conservation Society recommends health measures for Argentina's caiman ranches 2CAMH researcher discovers new gene that causes intellectual disability 2MIT control theory research: How to control complex networks 2MIT control theory research: How to control complex networks 3